Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136916 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 635
- Enrollment target
NCT00136916 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 635 participants.
The verdict
NCT00136916, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 635 participants
- Enrollment target
Study Summary
This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®. This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
Interventions
- DRUG Inhaled Insulin
- DRUG Subcutaneous insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2002-06 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136916
The ClinicalTrials.gov registry entry for NCT00136916 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 635 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhaled Insulin is the first listed.
NCT00136916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136916 about?
NCT00136916 is a clinical study titled "Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes". This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®. This study included a 2-year comparative treatment period followed by a 6-...
What is the current status of trial NCT00136916?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 2002-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00136916?
The interventions under investigation include: Inhaled Insulin (DRUG), Subcutaneous insulin (DRUG).
Who is sponsoring clinical trial NCT00136916?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.